Review



cyclic hexapeptide c5ar1 antagonist pmx 205  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress cyclic hexapeptide c5ar1 antagonist pmx 205
    A and B. In the spinal grey matter of AQP4-IgG-recipient mice, C5a-immunoreactivity was not seen in GFAP + astrocytes (A) and rarely seen in IBA1 + microglia/macrophage (B). The C5 proenzyme was seen only in luminal plasma, not in any CNS parenchymal cells . C. Triple immunostaining of lumbar cord of AQP4-IgG recipient mice revealed C5a in neutrophils (MPO+, left) and monocytes (CCR2-GFP + , enhanced by anti-GFP-IgG, right). D. The percentage of spinal cord cells expressing C5a immunoreactivity in AQP4-IgG-infused mice (determined by Image J) ( n =4 mice in each group). E. Colocalization analysis of C5a and MPO signals in C using Zen software (LSM980). F. After transcardiac washout of vasculature, lumbar cords from IgG-infused mice were dissociated enzymatically and subjected to high parametric flow cytometric analysis (Cytek). G. tSNE maps identifying CD11b + , Ly6G + , Cx3cr1 + and <t>C5aR1</t> + cells and their expression levels among CD45 + immune cells in the spinal cord, revealed that C5aR1 is expressed predominantly in microglial and neutrophil subsets. H. Public database ( Brain RNA-Seq ) documents that C5aR1 mRNA in normal mouse brain is predominantly expressed in microglia and macrophages. I. Flow cytometric plot shows that, after 3 days of AQP4-IgG infusion, greater numbers of neutrophils (Ly6G + cells) infiltrate the lumbar parenchyma in WT mice than in C5aR1 deficient mice. Percentages are quantified in the bar graph ( n = 4 mice in each group). J. Quantification of the percentage of infiltrating neutrophils (CD45 + CD11b + Ly6G + Ly6C − cells among CD45 + CD11b + cells) in spinal cords of wild-type and C5aR1 −/− mice at day 3 of AQP4-IgG infusion. K. Motor function, assessed by Rotarod performance (latency to fall), in WT and C5aR1 −/− mice infused with AQP4-IgG or (only C5aR1 −/− mice) normal mouse IgG (0.1 μg/μL, n = 6 mice per group). L. Motor function of mice assessed as fall latency from Rotarod; (time: F (8, 48) = 1.543, p =0.1675; treatment: F (1, 6) = 14.90, p = 0.0084; interaction: F (8, 39) = 2.070, p =0.0629; n = 6-7 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. One-way ANOVA, followed by Tukey’s post hoc multiple comparisons test in D. Unpaired Student t -test in J. Two-way repeated measures ANOVA with Sidak post hoc test in K. p < 0.05 was considered a significant difference.
    Cyclic Hexapeptide C5ar1 Antagonist Pmx 205, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cyclic hexapeptide c5ar1 antagonist pmx 205/product/MedChemExpress
    Average 93 stars, based on 10 article reviews
    cyclic hexapeptide c5ar1 antagonist pmx 205 - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Neutrophil-microglia interaction drives reversible motor dysfunction in neuromyelitis optica model induced by subarachnoid AQP4-IgG"

    Article Title: Neutrophil-microglia interaction drives reversible motor dysfunction in neuromyelitis optica model induced by subarachnoid AQP4-IgG

    Journal: bioRxiv

    doi: 10.1101/2025.08.22.671883

    A and B. In the spinal grey matter of AQP4-IgG-recipient mice, C5a-immunoreactivity was not seen in GFAP + astrocytes (A) and rarely seen in IBA1 + microglia/macrophage (B). The C5 proenzyme was seen only in luminal plasma, not in any CNS parenchymal cells . C. Triple immunostaining of lumbar cord of AQP4-IgG recipient mice revealed C5a in neutrophils (MPO+, left) and monocytes (CCR2-GFP + , enhanced by anti-GFP-IgG, right). D. The percentage of spinal cord cells expressing C5a immunoreactivity in AQP4-IgG-infused mice (determined by Image J) ( n =4 mice in each group). E. Colocalization analysis of C5a and MPO signals in C using Zen software (LSM980). F. After transcardiac washout of vasculature, lumbar cords from IgG-infused mice were dissociated enzymatically and subjected to high parametric flow cytometric analysis (Cytek). G. tSNE maps identifying CD11b + , Ly6G + , Cx3cr1 + and C5aR1 + cells and their expression levels among CD45 + immune cells in the spinal cord, revealed that C5aR1 is expressed predominantly in microglial and neutrophil subsets. H. Public database ( Brain RNA-Seq ) documents that C5aR1 mRNA in normal mouse brain is predominantly expressed in microglia and macrophages. I. Flow cytometric plot shows that, after 3 days of AQP4-IgG infusion, greater numbers of neutrophils (Ly6G + cells) infiltrate the lumbar parenchyma in WT mice than in C5aR1 deficient mice. Percentages are quantified in the bar graph ( n = 4 mice in each group). J. Quantification of the percentage of infiltrating neutrophils (CD45 + CD11b + Ly6G + Ly6C − cells among CD45 + CD11b + cells) in spinal cords of wild-type and C5aR1 −/− mice at day 3 of AQP4-IgG infusion. K. Motor function, assessed by Rotarod performance (latency to fall), in WT and C5aR1 −/− mice infused with AQP4-IgG or (only C5aR1 −/− mice) normal mouse IgG (0.1 μg/μL, n = 6 mice per group). L. Motor function of mice assessed as fall latency from Rotarod; (time: F (8, 48) = 1.543, p =0.1675; treatment: F (1, 6) = 14.90, p = 0.0084; interaction: F (8, 39) = 2.070, p =0.0629; n = 6-7 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. One-way ANOVA, followed by Tukey’s post hoc multiple comparisons test in D. Unpaired Student t -test in J. Two-way repeated measures ANOVA with Sidak post hoc test in K. p < 0.05 was considered a significant difference.
    Figure Legend Snippet: A and B. In the spinal grey matter of AQP4-IgG-recipient mice, C5a-immunoreactivity was not seen in GFAP + astrocytes (A) and rarely seen in IBA1 + microglia/macrophage (B). The C5 proenzyme was seen only in luminal plasma, not in any CNS parenchymal cells . C. Triple immunostaining of lumbar cord of AQP4-IgG recipient mice revealed C5a in neutrophils (MPO+, left) and monocytes (CCR2-GFP + , enhanced by anti-GFP-IgG, right). D. The percentage of spinal cord cells expressing C5a immunoreactivity in AQP4-IgG-infused mice (determined by Image J) ( n =4 mice in each group). E. Colocalization analysis of C5a and MPO signals in C using Zen software (LSM980). F. After transcardiac washout of vasculature, lumbar cords from IgG-infused mice were dissociated enzymatically and subjected to high parametric flow cytometric analysis (Cytek). G. tSNE maps identifying CD11b + , Ly6G + , Cx3cr1 + and C5aR1 + cells and their expression levels among CD45 + immune cells in the spinal cord, revealed that C5aR1 is expressed predominantly in microglial and neutrophil subsets. H. Public database ( Brain RNA-Seq ) documents that C5aR1 mRNA in normal mouse brain is predominantly expressed in microglia and macrophages. I. Flow cytometric plot shows that, after 3 days of AQP4-IgG infusion, greater numbers of neutrophils (Ly6G + cells) infiltrate the lumbar parenchyma in WT mice than in C5aR1 deficient mice. Percentages are quantified in the bar graph ( n = 4 mice in each group). J. Quantification of the percentage of infiltrating neutrophils (CD45 + CD11b + Ly6G + Ly6C − cells among CD45 + CD11b + cells) in spinal cords of wild-type and C5aR1 −/− mice at day 3 of AQP4-IgG infusion. K. Motor function, assessed by Rotarod performance (latency to fall), in WT and C5aR1 −/− mice infused with AQP4-IgG or (only C5aR1 −/− mice) normal mouse IgG (0.1 μg/μL, n = 6 mice per group). L. Motor function of mice assessed as fall latency from Rotarod; (time: F (8, 48) = 1.543, p =0.1675; treatment: F (1, 6) = 14.90, p = 0.0084; interaction: F (8, 39) = 2.070, p =0.0629; n = 6-7 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. One-way ANOVA, followed by Tukey’s post hoc multiple comparisons test in D. Unpaired Student t -test in J. Two-way repeated measures ANOVA with Sidak post hoc test in K. p < 0.05 was considered a significant difference.

    Techniques Used: Clinical Proteomics, Triple Immunostaining, Expressing, Software, RNA Sequencing

    A. Representative confocal images from lumbar cord of WT and C5aR1 -deficient mice infused with normal IgG or AQP4-IgG. Lysosomal CD68-immunoreactivity (red) is more abundant in microglia (green) of WT recipients of AQP4-IgG than in C5aR1 −/− recipients. Imaris 3D rendering images illustrate the magnitude of lysosomal expansion. B. Image J analysis of the percentage area occupied by lysosome inside microglia in the lumbar cord of different experimental groups (Treatment: F (1, 20) = 145.8, p < 0.0001; genotype: F (1, 20) = 1.144, p = 0.2975; n = 5-6 mice per group). C. Sholl analysis of microglial branching revealed by Imaris AI-powered filament tracing which counts the number of microglial filaments intersected by 1 μm spherical steps (Treatment: F (77, 3730) = 39.35, p < 0.0001; Radius: F (3, 95) = 17.02, p < 0.0001; n = 19-32 microglia from 5 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. Two-way (treatment × genotyping) ANO VA with Sidak post hoc multiple comparisons test in B. Two-way repeated measures ANOVA with Sidak post hoc test in C. p < 0.05 was considered significant difference.
    Figure Legend Snippet: A. Representative confocal images from lumbar cord of WT and C5aR1 -deficient mice infused with normal IgG or AQP4-IgG. Lysosomal CD68-immunoreactivity (red) is more abundant in microglia (green) of WT recipients of AQP4-IgG than in C5aR1 −/− recipients. Imaris 3D rendering images illustrate the magnitude of lysosomal expansion. B. Image J analysis of the percentage area occupied by lysosome inside microglia in the lumbar cord of different experimental groups (Treatment: F (1, 20) = 145.8, p < 0.0001; genotype: F (1, 20) = 1.144, p = 0.2975; n = 5-6 mice per group). C. Sholl analysis of microglial branching revealed by Imaris AI-powered filament tracing which counts the number of microglial filaments intersected by 1 μm spherical steps (Treatment: F (77, 3730) = 39.35, p < 0.0001; Radius: F (3, 95) = 17.02, p < 0.0001; n = 19-32 microglia from 5 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. Two-way (treatment × genotyping) ANO VA with Sidak post hoc multiple comparisons test in B. Two-way repeated measures ANOVA with Sidak post hoc test in C. p < 0.05 was considered significant difference.

    Techniques Used:

    A. Experimental design: WT mice were infused continuously with AQP4-IgG using osmotic pumps from day 0 through day 7; infusion was stopped on day 8. B-D. Quantification of Nissl bodies (B), Nissl area (C) and percentage area occupied by ChAT + motor neurons in grey matter of lumbar cord of Ctrl-IgG-infused mice at day 3, AQP4-IgG-infused mice at days 3, 14 and 28. Ctrl: (Nissl body count 251.5± 85.7/mm 2 , Ctrl Nissl body area: 4.928± 0.6 mm 2 , Ctrl ChAT signal area: 14.83 ± 1.8 mm 2 ); Day 3: (Nissl body count 165.8 ± 21.6/mm 2 , Nissl body area 3.0 ± 0.4 mm 2 , ChAT signal area: 4.1 ± 0.8 mm 2 ); Day 28: (Nissl body count: 278.8 ± 33.08/mm 2 , Nissl body area: 4.786 ± 0.6 mm 2 , ChAT signal area: 9.517 ± 1.8 mm 2 ). E-H. Representative immunostained images of Nissl bodies (red) in ventral gray matter (vGM) neurons of wild-type and C5aR1 −/− mice after 3 days’ Ctrl-IgG or AQP4-IgG infusion. Boxed areas are enlarged on the right. I, J. Numbers and sizes of Nissl body-positive neurons in ventral gray matter ( n = 8 mice per group). K. Representative motor neuron confocal images and quantification in ventral gray matter of WT mice infused with Ctrl-IgG or AQP4-IgG, and C5aR1 −/− mice infused with AQP4-IgG or control IgG (not shown). ANNA1[HuD] + (green); ChAT + (magenta). L, M. Numbers of ChAT + motor neurons (MNs) and their percentage among total neurons (ANNA1 [HuD] + in vGM. ( n = 4 mice per group). N. Representative images of BODIPY + lipid droplets (green) in ChAT + motor neurons (grey) and NeuN + neurons (grey) in ventral gray matter of AQP4-IgG-infused WT and C5aR1 −/− mice. 3D reconstruction of BODIPY + lipid and NeuN + neurons using Imaris (right). O. Quantification of lipid droplet numbers in the cytoplasm of NeuN + neurons in ventral gray matter of WT and C5aR1 deficient mice infused for 3 days with AQP4-IgG ( n = 20 neurons from 4 individual mice per group). P. Representative confocal images of 4HNE (peroxidative stress marker) in ChAT + motor neurons of WT and C5aR1 −/− mice infused with AQP4-IgG. Q and R. Q, Quantification of 4HNE and ChAT immunoreactivity intensities across 30 μm neuronal diameter; R, presented as mean ±SEM ( n =20 neurons from 4 individual mice per group). All data represent means ± SEM, all statistical tests are two-sided. Two-way (treatment × genotyping) ANOVA with Sidak post hoc test multiple comparisons test in I and J. One-way ANOVA with Tukey post hoc in B-D, L and M. Unpaired Student t -test in O and R. p < 0.05 was considered significant difference.
    Figure Legend Snippet: A. Experimental design: WT mice were infused continuously with AQP4-IgG using osmotic pumps from day 0 through day 7; infusion was stopped on day 8. B-D. Quantification of Nissl bodies (B), Nissl area (C) and percentage area occupied by ChAT + motor neurons in grey matter of lumbar cord of Ctrl-IgG-infused mice at day 3, AQP4-IgG-infused mice at days 3, 14 and 28. Ctrl: (Nissl body count 251.5± 85.7/mm 2 , Ctrl Nissl body area: 4.928± 0.6 mm 2 , Ctrl ChAT signal area: 14.83 ± 1.8 mm 2 ); Day 3: (Nissl body count 165.8 ± 21.6/mm 2 , Nissl body area 3.0 ± 0.4 mm 2 , ChAT signal area: 4.1 ± 0.8 mm 2 ); Day 28: (Nissl body count: 278.8 ± 33.08/mm 2 , Nissl body area: 4.786 ± 0.6 mm 2 , ChAT signal area: 9.517 ± 1.8 mm 2 ). E-H. Representative immunostained images of Nissl bodies (red) in ventral gray matter (vGM) neurons of wild-type and C5aR1 −/− mice after 3 days’ Ctrl-IgG or AQP4-IgG infusion. Boxed areas are enlarged on the right. I, J. Numbers and sizes of Nissl body-positive neurons in ventral gray matter ( n = 8 mice per group). K. Representative motor neuron confocal images and quantification in ventral gray matter of WT mice infused with Ctrl-IgG or AQP4-IgG, and C5aR1 −/− mice infused with AQP4-IgG or control IgG (not shown). ANNA1[HuD] + (green); ChAT + (magenta). L, M. Numbers of ChAT + motor neurons (MNs) and their percentage among total neurons (ANNA1 [HuD] + in vGM. ( n = 4 mice per group). N. Representative images of BODIPY + lipid droplets (green) in ChAT + motor neurons (grey) and NeuN + neurons (grey) in ventral gray matter of AQP4-IgG-infused WT and C5aR1 −/− mice. 3D reconstruction of BODIPY + lipid and NeuN + neurons using Imaris (right). O. Quantification of lipid droplet numbers in the cytoplasm of NeuN + neurons in ventral gray matter of WT and C5aR1 deficient mice infused for 3 days with AQP4-IgG ( n = 20 neurons from 4 individual mice per group). P. Representative confocal images of 4HNE (peroxidative stress marker) in ChAT + motor neurons of WT and C5aR1 −/− mice infused with AQP4-IgG. Q and R. Q, Quantification of 4HNE and ChAT immunoreactivity intensities across 30 μm neuronal diameter; R, presented as mean ±SEM ( n =20 neurons from 4 individual mice per group). All data represent means ± SEM, all statistical tests are two-sided. Two-way (treatment × genotyping) ANOVA with Sidak post hoc test multiple comparisons test in I and J. One-way ANOVA with Tukey post hoc in B-D, L and M. Unpaired Student t -test in O and R. p < 0.05 was considered significant difference.

    Techniques Used: Control, Marker



    Similar Products

    93
    MedChemExpress cyclic hexapeptide c5ar1 antagonist pmx 205
    A and B. In the spinal grey matter of AQP4-IgG-recipient mice, C5a-immunoreactivity was not seen in GFAP + astrocytes (A) and rarely seen in IBA1 + microglia/macrophage (B). The C5 proenzyme was seen only in luminal plasma, not in any CNS parenchymal cells . C. Triple immunostaining of lumbar cord of AQP4-IgG recipient mice revealed C5a in neutrophils (MPO+, left) and monocytes (CCR2-GFP + , enhanced by anti-GFP-IgG, right). D. The percentage of spinal cord cells expressing C5a immunoreactivity in AQP4-IgG-infused mice (determined by Image J) ( n =4 mice in each group). E. Colocalization analysis of C5a and MPO signals in C using Zen software (LSM980). F. After transcardiac washout of vasculature, lumbar cords from IgG-infused mice were dissociated enzymatically and subjected to high parametric flow cytometric analysis (Cytek). G. tSNE maps identifying CD11b + , Ly6G + , Cx3cr1 + and <t>C5aR1</t> + cells and their expression levels among CD45 + immune cells in the spinal cord, revealed that C5aR1 is expressed predominantly in microglial and neutrophil subsets. H. Public database ( Brain RNA-Seq ) documents that C5aR1 mRNA in normal mouse brain is predominantly expressed in microglia and macrophages. I. Flow cytometric plot shows that, after 3 days of AQP4-IgG infusion, greater numbers of neutrophils (Ly6G + cells) infiltrate the lumbar parenchyma in WT mice than in C5aR1 deficient mice. Percentages are quantified in the bar graph ( n = 4 mice in each group). J. Quantification of the percentage of infiltrating neutrophils (CD45 + CD11b + Ly6G + Ly6C − cells among CD45 + CD11b + cells) in spinal cords of wild-type and C5aR1 −/− mice at day 3 of AQP4-IgG infusion. K. Motor function, assessed by Rotarod performance (latency to fall), in WT and C5aR1 −/− mice infused with AQP4-IgG or (only C5aR1 −/− mice) normal mouse IgG (0.1 μg/μL, n = 6 mice per group). L. Motor function of mice assessed as fall latency from Rotarod; (time: F (8, 48) = 1.543, p =0.1675; treatment: F (1, 6) = 14.90, p = 0.0084; interaction: F (8, 39) = 2.070, p =0.0629; n = 6-7 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. One-way ANOVA, followed by Tukey’s post hoc multiple comparisons test in D. Unpaired Student t -test in J. Two-way repeated measures ANOVA with Sidak post hoc test in K. p < 0.05 was considered a significant difference.
    Cyclic Hexapeptide C5ar1 Antagonist Pmx 205, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cyclic hexapeptide c5ar1 antagonist pmx 205/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    cyclic hexapeptide c5ar1 antagonist pmx 205 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress pmx205
    A and B. In the spinal grey matter of AQP4-IgG-recipient mice, C5a-immunoreactivity was not seen in GFAP + astrocytes (A) and rarely seen in IBA1 + microglia/macrophage (B). The C5 proenzyme was seen only in luminal plasma, not in any CNS parenchymal cells . C. Triple immunostaining of lumbar cord of AQP4-IgG recipient mice revealed C5a in neutrophils (MPO+, left) and monocytes (CCR2-GFP + , enhanced by anti-GFP-IgG, right). D. The percentage of spinal cord cells expressing C5a immunoreactivity in AQP4-IgG-infused mice (determined by Image J) ( n =4 mice in each group). E. Colocalization analysis of C5a and MPO signals in C using Zen software (LSM980). F. After transcardiac washout of vasculature, lumbar cords from IgG-infused mice were dissociated enzymatically and subjected to high parametric flow cytometric analysis (Cytek). G. tSNE maps identifying CD11b + , Ly6G + , Cx3cr1 + and <t>C5aR1</t> + cells and their expression levels among CD45 + immune cells in the spinal cord, revealed that C5aR1 is expressed predominantly in microglial and neutrophil subsets. H. Public database ( Brain RNA-Seq ) documents that C5aR1 mRNA in normal mouse brain is predominantly expressed in microglia and macrophages. I. Flow cytometric plot shows that, after 3 days of AQP4-IgG infusion, greater numbers of neutrophils (Ly6G + cells) infiltrate the lumbar parenchyma in WT mice than in C5aR1 deficient mice. Percentages are quantified in the bar graph ( n = 4 mice in each group). J. Quantification of the percentage of infiltrating neutrophils (CD45 + CD11b + Ly6G + Ly6C − cells among CD45 + CD11b + cells) in spinal cords of wild-type and C5aR1 −/− mice at day 3 of AQP4-IgG infusion. K. Motor function, assessed by Rotarod performance (latency to fall), in WT and C5aR1 −/− mice infused with AQP4-IgG or (only C5aR1 −/− mice) normal mouse IgG (0.1 μg/μL, n = 6 mice per group). L. Motor function of mice assessed as fall latency from Rotarod; (time: F (8, 48) = 1.543, p =0.1675; treatment: F (1, 6) = 14.90, p = 0.0084; interaction: F (8, 39) = 2.070, p =0.0629; n = 6-7 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. One-way ANOVA, followed by Tukey’s post hoc multiple comparisons test in D. Unpaired Student t -test in J. Two-way repeated measures ANOVA with Sidak post hoc test in K. p < 0.05 was considered a significant difference.
    Pmx205, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pmx205/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    pmx205 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress c5ar1 antagonist pmx205
    A and B. In the spinal grey matter of AQP4-IgG-recipient mice, C5a-immunoreactivity was not seen in GFAP + astrocytes (A) and rarely seen in IBA1 + microglia/macrophage (B). The C5 proenzyme was seen only in luminal plasma, not in any CNS parenchymal cells . C. Triple immunostaining of lumbar cord of AQP4-IgG recipient mice revealed C5a in neutrophils (MPO+, left) and monocytes (CCR2-GFP + , enhanced by anti-GFP-IgG, right). D. The percentage of spinal cord cells expressing C5a immunoreactivity in AQP4-IgG-infused mice (determined by Image J) ( n =4 mice in each group). E. Colocalization analysis of C5a and MPO signals in C using Zen software (LSM980). F. After transcardiac washout of vasculature, lumbar cords from IgG-infused mice were dissociated enzymatically and subjected to high parametric flow cytometric analysis (Cytek). G. tSNE maps identifying CD11b + , Ly6G + , Cx3cr1 + and <t>C5aR1</t> + cells and their expression levels among CD45 + immune cells in the spinal cord, revealed that C5aR1 is expressed predominantly in microglial and neutrophil subsets. H. Public database ( Brain RNA-Seq ) documents that C5aR1 mRNA in normal mouse brain is predominantly expressed in microglia and macrophages. I. Flow cytometric plot shows that, after 3 days of AQP4-IgG infusion, greater numbers of neutrophils (Ly6G + cells) infiltrate the lumbar parenchyma in WT mice than in C5aR1 deficient mice. Percentages are quantified in the bar graph ( n = 4 mice in each group). J. Quantification of the percentage of infiltrating neutrophils (CD45 + CD11b + Ly6G + Ly6C − cells among CD45 + CD11b + cells) in spinal cords of wild-type and C5aR1 −/− mice at day 3 of AQP4-IgG infusion. K. Motor function, assessed by Rotarod performance (latency to fall), in WT and C5aR1 −/− mice infused with AQP4-IgG or (only C5aR1 −/− mice) normal mouse IgG (0.1 μg/μL, n = 6 mice per group). L. Motor function of mice assessed as fall latency from Rotarod; (time: F (8, 48) = 1.543, p =0.1675; treatment: F (1, 6) = 14.90, p = 0.0084; interaction: F (8, 39) = 2.070, p =0.0629; n = 6-7 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. One-way ANOVA, followed by Tukey’s post hoc multiple comparisons test in D. Unpaired Student t -test in J. Two-way repeated measures ANOVA with Sidak post hoc test in K. p < 0.05 was considered a significant difference.
    C5ar1 Antagonist Pmx205, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c5ar1 antagonist pmx205/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    c5ar1 antagonist pmx205 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress c5a
    A and B. In the spinal grey matter of AQP4-IgG-recipient mice, C5a-immunoreactivity was not seen in GFAP + astrocytes (A) and rarely seen in IBA1 + microglia/macrophage (B). The C5 proenzyme was seen only in luminal plasma, not in any CNS parenchymal cells . C. Triple immunostaining of lumbar cord of AQP4-IgG recipient mice revealed C5a in neutrophils (MPO+, left) and monocytes (CCR2-GFP + , enhanced by anti-GFP-IgG, right). D. The percentage of spinal cord cells expressing C5a immunoreactivity in AQP4-IgG-infused mice (determined by Image J) ( n =4 mice in each group). E. Colocalization analysis of C5a and MPO signals in C using Zen software (LSM980). F. After transcardiac washout of vasculature, lumbar cords from IgG-infused mice were dissociated enzymatically and subjected to high parametric flow cytometric analysis (Cytek). G. tSNE maps identifying CD11b + , Ly6G + , Cx3cr1 + and <t>C5aR1</t> + cells and their expression levels among CD45 + immune cells in the spinal cord, revealed that C5aR1 is expressed predominantly in microglial and neutrophil subsets. H. Public database ( Brain RNA-Seq ) documents that C5aR1 mRNA in normal mouse brain is predominantly expressed in microglia and macrophages. I. Flow cytometric plot shows that, after 3 days of AQP4-IgG infusion, greater numbers of neutrophils (Ly6G + cells) infiltrate the lumbar parenchyma in WT mice than in C5aR1 deficient mice. Percentages are quantified in the bar graph ( n = 4 mice in each group). J. Quantification of the percentage of infiltrating neutrophils (CD45 + CD11b + Ly6G + Ly6C − cells among CD45 + CD11b + cells) in spinal cords of wild-type and C5aR1 −/− mice at day 3 of AQP4-IgG infusion. K. Motor function, assessed by Rotarod performance (latency to fall), in WT and C5aR1 −/− mice infused with AQP4-IgG or (only C5aR1 −/− mice) normal mouse IgG (0.1 μg/μL, n = 6 mice per group). L. Motor function of mice assessed as fall latency from Rotarod; (time: F (8, 48) = 1.543, p =0.1675; treatment: F (1, 6) = 14.90, p = 0.0084; interaction: F (8, 39) = 2.070, p =0.0629; n = 6-7 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. One-way ANOVA, followed by Tukey’s post hoc multiple comparisons test in D. Unpaired Student t -test in J. Two-way repeated measures ANOVA with Sidak post hoc test in K. p < 0.05 was considered a significant difference.
    C5a, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c5a/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    c5a - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    90
    PepTech Corporation pmx-205
    A and B. In the spinal grey matter of AQP4-IgG-recipient mice, C5a-immunoreactivity was not seen in GFAP + astrocytes (A) and rarely seen in IBA1 + microglia/macrophage (B). The C5 proenzyme was seen only in luminal plasma, not in any CNS parenchymal cells . C. Triple immunostaining of lumbar cord of AQP4-IgG recipient mice revealed C5a in neutrophils (MPO+, left) and monocytes (CCR2-GFP + , enhanced by anti-GFP-IgG, right). D. The percentage of spinal cord cells expressing C5a immunoreactivity in AQP4-IgG-infused mice (determined by Image J) ( n =4 mice in each group). E. Colocalization analysis of C5a and MPO signals in C using Zen software (LSM980). F. After transcardiac washout of vasculature, lumbar cords from IgG-infused mice were dissociated enzymatically and subjected to high parametric flow cytometric analysis (Cytek). G. tSNE maps identifying CD11b + , Ly6G + , Cx3cr1 + and <t>C5aR1</t> + cells and their expression levels among CD45 + immune cells in the spinal cord, revealed that C5aR1 is expressed predominantly in microglial and neutrophil subsets. H. Public database ( Brain RNA-Seq ) documents that C5aR1 mRNA in normal mouse brain is predominantly expressed in microglia and macrophages. I. Flow cytometric plot shows that, after 3 days of AQP4-IgG infusion, greater numbers of neutrophils (Ly6G + cells) infiltrate the lumbar parenchyma in WT mice than in C5aR1 deficient mice. Percentages are quantified in the bar graph ( n = 4 mice in each group). J. Quantification of the percentage of infiltrating neutrophils (CD45 + CD11b + Ly6G + Ly6C − cells among CD45 + CD11b + cells) in spinal cords of wild-type and C5aR1 −/− mice at day 3 of AQP4-IgG infusion. K. Motor function, assessed by Rotarod performance (latency to fall), in WT and C5aR1 −/− mice infused with AQP4-IgG or (only C5aR1 −/− mice) normal mouse IgG (0.1 μg/μL, n = 6 mice per group). L. Motor function of mice assessed as fall latency from Rotarod; (time: F (8, 48) = 1.543, p =0.1675; treatment: F (1, 6) = 14.90, p = 0.0084; interaction: F (8, 39) = 2.070, p =0.0629; n = 6-7 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. One-way ANOVA, followed by Tukey’s post hoc multiple comparisons test in D. Unpaired Student t -test in J. Two-way repeated measures ANOVA with Sidak post hoc test in K. p < 0.05 was considered a significant difference.
    Pmx 205, supplied by PepTech Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pmx-205/product/PepTech Corporation
    Average 90 stars, based on 1 article reviews
    pmx-205 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    93
    MedChemExpress c5ar antagonist pmx205
    A TEM was used to visualize ferroptosis in U87 and U251 cells. Scale bars, 2 μm, and 500 nm. B Protein expression of GPX4 after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, ** P < 0.01, *** P < 0.001). C Protein expression of GPX4 after treatment with different concentrations of <t>PMX205,</t> and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). D Abundance of 4-HNE after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, ** P < 0.01). E Intracellular MDA levels after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). F GSH level after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). G Relative ROS levels after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). H Oxidation-induced fluorescence of C11-BODIPY 581/591 in U87/U251 cells transfected with si-C5aR1. Green fluorescence indicates the oxidation reaction (O-BOD), while red fluorescence indicates the reduction reaction (N-BOD) The related quantitative analysis is shown, ( n = 3, means ± SD, ** P < 0.01). Scale bar, 50 μm.
    C5ar Antagonist Pmx205, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c5ar antagonist pmx205/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    c5ar antagonist pmx205 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    Image Search Results


    A and B. In the spinal grey matter of AQP4-IgG-recipient mice, C5a-immunoreactivity was not seen in GFAP + astrocytes (A) and rarely seen in IBA1 + microglia/macrophage (B). The C5 proenzyme was seen only in luminal plasma, not in any CNS parenchymal cells . C. Triple immunostaining of lumbar cord of AQP4-IgG recipient mice revealed C5a in neutrophils (MPO+, left) and monocytes (CCR2-GFP + , enhanced by anti-GFP-IgG, right). D. The percentage of spinal cord cells expressing C5a immunoreactivity in AQP4-IgG-infused mice (determined by Image J) ( n =4 mice in each group). E. Colocalization analysis of C5a and MPO signals in C using Zen software (LSM980). F. After transcardiac washout of vasculature, lumbar cords from IgG-infused mice were dissociated enzymatically and subjected to high parametric flow cytometric analysis (Cytek). G. tSNE maps identifying CD11b + , Ly6G + , Cx3cr1 + and C5aR1 + cells and their expression levels among CD45 + immune cells in the spinal cord, revealed that C5aR1 is expressed predominantly in microglial and neutrophil subsets. H. Public database ( Brain RNA-Seq ) documents that C5aR1 mRNA in normal mouse brain is predominantly expressed in microglia and macrophages. I. Flow cytometric plot shows that, after 3 days of AQP4-IgG infusion, greater numbers of neutrophils (Ly6G + cells) infiltrate the lumbar parenchyma in WT mice than in C5aR1 deficient mice. Percentages are quantified in the bar graph ( n = 4 mice in each group). J. Quantification of the percentage of infiltrating neutrophils (CD45 + CD11b + Ly6G + Ly6C − cells among CD45 + CD11b + cells) in spinal cords of wild-type and C5aR1 −/− mice at day 3 of AQP4-IgG infusion. K. Motor function, assessed by Rotarod performance (latency to fall), in WT and C5aR1 −/− mice infused with AQP4-IgG or (only C5aR1 −/− mice) normal mouse IgG (0.1 μg/μL, n = 6 mice per group). L. Motor function of mice assessed as fall latency from Rotarod; (time: F (8, 48) = 1.543, p =0.1675; treatment: F (1, 6) = 14.90, p = 0.0084; interaction: F (8, 39) = 2.070, p =0.0629; n = 6-7 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. One-way ANOVA, followed by Tukey’s post hoc multiple comparisons test in D. Unpaired Student t -test in J. Two-way repeated measures ANOVA with Sidak post hoc test in K. p < 0.05 was considered a significant difference.

    Journal: bioRxiv

    Article Title: Neutrophil-microglia interaction drives reversible motor dysfunction in neuromyelitis optica model induced by subarachnoid AQP4-IgG

    doi: 10.1101/2025.08.22.671883

    Figure Lengend Snippet: A and B. In the spinal grey matter of AQP4-IgG-recipient mice, C5a-immunoreactivity was not seen in GFAP + astrocytes (A) and rarely seen in IBA1 + microglia/macrophage (B). The C5 proenzyme was seen only in luminal plasma, not in any CNS parenchymal cells . C. Triple immunostaining of lumbar cord of AQP4-IgG recipient mice revealed C5a in neutrophils (MPO+, left) and monocytes (CCR2-GFP + , enhanced by anti-GFP-IgG, right). D. The percentage of spinal cord cells expressing C5a immunoreactivity in AQP4-IgG-infused mice (determined by Image J) ( n =4 mice in each group). E. Colocalization analysis of C5a and MPO signals in C using Zen software (LSM980). F. After transcardiac washout of vasculature, lumbar cords from IgG-infused mice were dissociated enzymatically and subjected to high parametric flow cytometric analysis (Cytek). G. tSNE maps identifying CD11b + , Ly6G + , Cx3cr1 + and C5aR1 + cells and their expression levels among CD45 + immune cells in the spinal cord, revealed that C5aR1 is expressed predominantly in microglial and neutrophil subsets. H. Public database ( Brain RNA-Seq ) documents that C5aR1 mRNA in normal mouse brain is predominantly expressed in microglia and macrophages. I. Flow cytometric plot shows that, after 3 days of AQP4-IgG infusion, greater numbers of neutrophils (Ly6G + cells) infiltrate the lumbar parenchyma in WT mice than in C5aR1 deficient mice. Percentages are quantified in the bar graph ( n = 4 mice in each group). J. Quantification of the percentage of infiltrating neutrophils (CD45 + CD11b + Ly6G + Ly6C − cells among CD45 + CD11b + cells) in spinal cords of wild-type and C5aR1 −/− mice at day 3 of AQP4-IgG infusion. K. Motor function, assessed by Rotarod performance (latency to fall), in WT and C5aR1 −/− mice infused with AQP4-IgG or (only C5aR1 −/− mice) normal mouse IgG (0.1 μg/μL, n = 6 mice per group). L. Motor function of mice assessed as fall latency from Rotarod; (time: F (8, 48) = 1.543, p =0.1675; treatment: F (1, 6) = 14.90, p = 0.0084; interaction: F (8, 39) = 2.070, p =0.0629; n = 6-7 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. One-way ANOVA, followed by Tukey’s post hoc multiple comparisons test in D. Unpaired Student t -test in J. Two-way repeated measures ANOVA with Sidak post hoc test in K. p < 0.05 was considered a significant difference.

    Article Snippet: Trifluoroacetate was removed from the cyclic hexapeptide C5aR1 antagonist PMX 205 (HY-110136 A; MedChemExpress, NJ, USA) by repeated hydrochloric acid exchange followed by lyophilization .

    Techniques: Clinical Proteomics, Triple Immunostaining, Expressing, Software, RNA Sequencing

    A. Representative confocal images from lumbar cord of WT and C5aR1 -deficient mice infused with normal IgG or AQP4-IgG. Lysosomal CD68-immunoreactivity (red) is more abundant in microglia (green) of WT recipients of AQP4-IgG than in C5aR1 −/− recipients. Imaris 3D rendering images illustrate the magnitude of lysosomal expansion. B. Image J analysis of the percentage area occupied by lysosome inside microglia in the lumbar cord of different experimental groups (Treatment: F (1, 20) = 145.8, p < 0.0001; genotype: F (1, 20) = 1.144, p = 0.2975; n = 5-6 mice per group). C. Sholl analysis of microglial branching revealed by Imaris AI-powered filament tracing which counts the number of microglial filaments intersected by 1 μm spherical steps (Treatment: F (77, 3730) = 39.35, p < 0.0001; Radius: F (3, 95) = 17.02, p < 0.0001; n = 19-32 microglia from 5 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. Two-way (treatment × genotyping) ANO VA with Sidak post hoc multiple comparisons test in B. Two-way repeated measures ANOVA with Sidak post hoc test in C. p < 0.05 was considered significant difference.

    Journal: bioRxiv

    Article Title: Neutrophil-microglia interaction drives reversible motor dysfunction in neuromyelitis optica model induced by subarachnoid AQP4-IgG

    doi: 10.1101/2025.08.22.671883

    Figure Lengend Snippet: A. Representative confocal images from lumbar cord of WT and C5aR1 -deficient mice infused with normal IgG or AQP4-IgG. Lysosomal CD68-immunoreactivity (red) is more abundant in microglia (green) of WT recipients of AQP4-IgG than in C5aR1 −/− recipients. Imaris 3D rendering images illustrate the magnitude of lysosomal expansion. B. Image J analysis of the percentage area occupied by lysosome inside microglia in the lumbar cord of different experimental groups (Treatment: F (1, 20) = 145.8, p < 0.0001; genotype: F (1, 20) = 1.144, p = 0.2975; n = 5-6 mice per group). C. Sholl analysis of microglial branching revealed by Imaris AI-powered filament tracing which counts the number of microglial filaments intersected by 1 μm spherical steps (Treatment: F (77, 3730) = 39.35, p < 0.0001; Radius: F (3, 95) = 17.02, p < 0.0001; n = 19-32 microglia from 5 mice per group). In all graphs, data represent means ± SEM and all statistical tests are two-sided. Two-way (treatment × genotyping) ANO VA with Sidak post hoc multiple comparisons test in B. Two-way repeated measures ANOVA with Sidak post hoc test in C. p < 0.05 was considered significant difference.

    Article Snippet: Trifluoroacetate was removed from the cyclic hexapeptide C5aR1 antagonist PMX 205 (HY-110136 A; MedChemExpress, NJ, USA) by repeated hydrochloric acid exchange followed by lyophilization .

    Techniques:

    A. Experimental design: WT mice were infused continuously with AQP4-IgG using osmotic pumps from day 0 through day 7; infusion was stopped on day 8. B-D. Quantification of Nissl bodies (B), Nissl area (C) and percentage area occupied by ChAT + motor neurons in grey matter of lumbar cord of Ctrl-IgG-infused mice at day 3, AQP4-IgG-infused mice at days 3, 14 and 28. Ctrl: (Nissl body count 251.5± 85.7/mm 2 , Ctrl Nissl body area: 4.928± 0.6 mm 2 , Ctrl ChAT signal area: 14.83 ± 1.8 mm 2 ); Day 3: (Nissl body count 165.8 ± 21.6/mm 2 , Nissl body area 3.0 ± 0.4 mm 2 , ChAT signal area: 4.1 ± 0.8 mm 2 ); Day 28: (Nissl body count: 278.8 ± 33.08/mm 2 , Nissl body area: 4.786 ± 0.6 mm 2 , ChAT signal area: 9.517 ± 1.8 mm 2 ). E-H. Representative immunostained images of Nissl bodies (red) in ventral gray matter (vGM) neurons of wild-type and C5aR1 −/− mice after 3 days’ Ctrl-IgG or AQP4-IgG infusion. Boxed areas are enlarged on the right. I, J. Numbers and sizes of Nissl body-positive neurons in ventral gray matter ( n = 8 mice per group). K. Representative motor neuron confocal images and quantification in ventral gray matter of WT mice infused with Ctrl-IgG or AQP4-IgG, and C5aR1 −/− mice infused with AQP4-IgG or control IgG (not shown). ANNA1[HuD] + (green); ChAT + (magenta). L, M. Numbers of ChAT + motor neurons (MNs) and their percentage among total neurons (ANNA1 [HuD] + in vGM. ( n = 4 mice per group). N. Representative images of BODIPY + lipid droplets (green) in ChAT + motor neurons (grey) and NeuN + neurons (grey) in ventral gray matter of AQP4-IgG-infused WT and C5aR1 −/− mice. 3D reconstruction of BODIPY + lipid and NeuN + neurons using Imaris (right). O. Quantification of lipid droplet numbers in the cytoplasm of NeuN + neurons in ventral gray matter of WT and C5aR1 deficient mice infused for 3 days with AQP4-IgG ( n = 20 neurons from 4 individual mice per group). P. Representative confocal images of 4HNE (peroxidative stress marker) in ChAT + motor neurons of WT and C5aR1 −/− mice infused with AQP4-IgG. Q and R. Q, Quantification of 4HNE and ChAT immunoreactivity intensities across 30 μm neuronal diameter; R, presented as mean ±SEM ( n =20 neurons from 4 individual mice per group). All data represent means ± SEM, all statistical tests are two-sided. Two-way (treatment × genotyping) ANOVA with Sidak post hoc test multiple comparisons test in I and J. One-way ANOVA with Tukey post hoc in B-D, L and M. Unpaired Student t -test in O and R. p < 0.05 was considered significant difference.

    Journal: bioRxiv

    Article Title: Neutrophil-microglia interaction drives reversible motor dysfunction in neuromyelitis optica model induced by subarachnoid AQP4-IgG

    doi: 10.1101/2025.08.22.671883

    Figure Lengend Snippet: A. Experimental design: WT mice were infused continuously with AQP4-IgG using osmotic pumps from day 0 through day 7; infusion was stopped on day 8. B-D. Quantification of Nissl bodies (B), Nissl area (C) and percentage area occupied by ChAT + motor neurons in grey matter of lumbar cord of Ctrl-IgG-infused mice at day 3, AQP4-IgG-infused mice at days 3, 14 and 28. Ctrl: (Nissl body count 251.5± 85.7/mm 2 , Ctrl Nissl body area: 4.928± 0.6 mm 2 , Ctrl ChAT signal area: 14.83 ± 1.8 mm 2 ); Day 3: (Nissl body count 165.8 ± 21.6/mm 2 , Nissl body area 3.0 ± 0.4 mm 2 , ChAT signal area: 4.1 ± 0.8 mm 2 ); Day 28: (Nissl body count: 278.8 ± 33.08/mm 2 , Nissl body area: 4.786 ± 0.6 mm 2 , ChAT signal area: 9.517 ± 1.8 mm 2 ). E-H. Representative immunostained images of Nissl bodies (red) in ventral gray matter (vGM) neurons of wild-type and C5aR1 −/− mice after 3 days’ Ctrl-IgG or AQP4-IgG infusion. Boxed areas are enlarged on the right. I, J. Numbers and sizes of Nissl body-positive neurons in ventral gray matter ( n = 8 mice per group). K. Representative motor neuron confocal images and quantification in ventral gray matter of WT mice infused with Ctrl-IgG or AQP4-IgG, and C5aR1 −/− mice infused with AQP4-IgG or control IgG (not shown). ANNA1[HuD] + (green); ChAT + (magenta). L, M. Numbers of ChAT + motor neurons (MNs) and their percentage among total neurons (ANNA1 [HuD] + in vGM. ( n = 4 mice per group). N. Representative images of BODIPY + lipid droplets (green) in ChAT + motor neurons (grey) and NeuN + neurons (grey) in ventral gray matter of AQP4-IgG-infused WT and C5aR1 −/− mice. 3D reconstruction of BODIPY + lipid and NeuN + neurons using Imaris (right). O. Quantification of lipid droplet numbers in the cytoplasm of NeuN + neurons in ventral gray matter of WT and C5aR1 deficient mice infused for 3 days with AQP4-IgG ( n = 20 neurons from 4 individual mice per group). P. Representative confocal images of 4HNE (peroxidative stress marker) in ChAT + motor neurons of WT and C5aR1 −/− mice infused with AQP4-IgG. Q and R. Q, Quantification of 4HNE and ChAT immunoreactivity intensities across 30 μm neuronal diameter; R, presented as mean ±SEM ( n =20 neurons from 4 individual mice per group). All data represent means ± SEM, all statistical tests are two-sided. Two-way (treatment × genotyping) ANOVA with Sidak post hoc test multiple comparisons test in I and J. One-way ANOVA with Tukey post hoc in B-D, L and M. Unpaired Student t -test in O and R. p < 0.05 was considered significant difference.

    Article Snippet: Trifluoroacetate was removed from the cyclic hexapeptide C5aR1 antagonist PMX 205 (HY-110136 A; MedChemExpress, NJ, USA) by repeated hydrochloric acid exchange followed by lyophilization .

    Techniques: Control, Marker

    A TEM was used to visualize ferroptosis in U87 and U251 cells. Scale bars, 2 μm, and 500 nm. B Protein expression of GPX4 after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, ** P < 0.01, *** P < 0.001). C Protein expression of GPX4 after treatment with different concentrations of PMX205, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). D Abundance of 4-HNE after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, ** P < 0.01). E Intracellular MDA levels after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). F GSH level after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). G Relative ROS levels after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). H Oxidation-induced fluorescence of C11-BODIPY 581/591 in U87/U251 cells transfected with si-C5aR1. Green fluorescence indicates the oxidation reaction (O-BOD), while red fluorescence indicates the reduction reaction (N-BOD) The related quantitative analysis is shown, ( n = 3, means ± SD, ** P < 0.01). Scale bar, 50 μm.

    Journal: Cell Death & Disease

    Article Title: Intracellular C5aR1 inhibits ferroptosis in glioblastoma through METTL3-dependent m6A methylation of GPX4

    doi: 10.1038/s41419-024-06963-5

    Figure Lengend Snippet: A TEM was used to visualize ferroptosis in U87 and U251 cells. Scale bars, 2 μm, and 500 nm. B Protein expression of GPX4 after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, ** P < 0.01, *** P < 0.001). C Protein expression of GPX4 after treatment with different concentrations of PMX205, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). D Abundance of 4-HNE after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, ** P < 0.01). E Intracellular MDA levels after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). F GSH level after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). G Relative ROS levels after C5aR1 knockdown, and the related quantitative analysis, ( n = 3, means ± SD, * P < 0.05). H Oxidation-induced fluorescence of C11-BODIPY 581/591 in U87/U251 cells transfected with si-C5aR1. Green fluorescence indicates the oxidation reaction (O-BOD), while red fluorescence indicates the reduction reaction (N-BOD) The related quantitative analysis is shown, ( n = 3, means ± SD, ** P < 0.01). Scale bar, 50 μm.

    Article Snippet: The apoptosis inhibitor Z-VAD-FMK (HY-16658B, MedChemExpress MCE USA), the ferroptosis inhibitors ferrostatin-1 (HY-100579, MCE, USA) and liproxstatin-1 (HY-12726, MCE, USA), the necroptosis inhibitor necrostatin-1 (HY-15760, MCE, USA), the autophagy inhibitor 3-methyladenine (HY-19312, MCE, USA) and the C5aR antagonist PMX205 (HY-110136A, MCE, USA) were used.

    Techniques: Expressing, Knockdown, Fluorescence, Transfection